Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Horvath, A; Haller, R; Feldbacher, N; Habisch, H; Žukauskaitė, K; Madl, T; Stadlbauer, V.
Probiotic Therapy of Gastrointestinal Symptoms During COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled, Remote Study.
Nutrients. 2024; 16(22): Doi: 10.3390/nu16223970 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz

Horvath Angela

Stadlbauer-Köllner Vanessa

Co-authors Med Uni Graz

Feldbacher Nicole

Habisch Hansjörg

Haller Rosa

Madl Tobias

Zukauskaite Kristina

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND: The novel coronavirus (SARS-CoV-2) led to gastrointestinal manifestations in up to 50% of cases, with diarrhea being common, and probiotics have been suggested as a potential treatment. AIM: This study aimed to assess changes in the microbiome and the effects of a multispecies probiotic in patients with COVID-19 in home quarantine through a fully remote telemedical approach. METHODS: Thirty patients were randomized to receive either the Ecologic AAD probiotic (Winclove Probiotics, Amsterdam, The Netherlands), on the market as OMNi-BiOTiC 10 (Allergosan, Austria), or a placebo for 30 days in a 2:1 ratio. Respiratory and gastrointestinal symptoms were monitored in 2-10-day intervals via online surveys, and five stool samples were collected during the 30-day study period for microbiome and metabolomics analyses. Twenty-four healthy volunteers served as controls. RESULTS: Of the 30 patients, 26 completed this study (10 placebo, 16 probiotic). Patients reported respiratory symptoms and a diminished gastrointestinal quality of life, both of which improved significantly during the study period, irrespective of the intervention. Compared to controls, infected patients showed significant alterations in the fecal microbiome (p = 0.002), including an increase in Bacteroidetes and decreases in Christensenellaceae, Ruminococcaceae, and Gammaproteobacteria, along with metabolomic changes. Probiotic treatment significantly modulated the patients' microbiome beta diversity (p = 0.001) and introduced the Enterococcus faecium W54 strain. Symptoms, COVID-19-related taxa, and the fecal metabolome were not affected by the intervention. CONCLUSIONS: Patients with mild COVID-19 disease in home quarantine exhibited respiratory symptoms, a reduced gastrointestinal quality of life, and changes in the fecal microbiome and metabolome.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Probiotics - therapeutic use, administration & dosage

Male - administration & dosage

COVID-19 - therapy

Female - administration & dosage

Gastrointestinal Microbiome - administration & dosage

Middle Aged - administration & dosage

Double-Blind Method - administration & dosage

Feces - microbiology

Adult - administration & dosage

SARS-CoV-2 - administration & dosage

Quality of Life - administration & dosage

Gastrointestinal Diseases - therapy, microbiology

Aged - administration & dosage

Quarantine - administration & dosage

Telemedicine - administration & dosage

Find related publications in this database (Keywords)

COVID-19

probiotic

microbiome

patient-reported outcomes

quality of life

Enterococcus faecium

© Med Uni Graz • Imprint